Lv2
126 积分 2021-08-18 加入
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
6小时前
已完结
Revolutionizing the battle against locally advanced breast cancer: A comprehensive insight into neoadjuvant radiotherapy
6天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
7天前
已完结
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors
20天前
已完结
What if all participants get the same treatment? An ethical perspective on single arm trials
28天前
已关闭
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
1个月前
已关闭
Challenges in the Design and Interpretation of Noninferiority Trials
1个月前
已完结
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
1个月前
已完结
Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies
1个月前
已关闭
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
